Jade Pharma To Set Up Biopharmaceutical Base In Jiangxi
This article was originally published in PharmAsia News
Executive Summary
U.S.-listed Jade Pharmahas signed a letter of intent with Sanghai Economic and Technological Development Zone in Jiangxi province to set up the company's biopharmaceutical projects base in Sanghai with an investment of $150 million. The project's first phase, with $25 million in funding, will cover the construction of a R&D base this year. The second phase, to begin in 2010, will include the building of a cultivation center for anticancer plants. Jade Pharma is a pharmaceutical company that focuses on early diagnostic testing technology for cancer and other diseases. Jade also engages in R&D, production and trading of biopharmaceutical products and medicines. (Click here for more - Chinese Language)